This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

E. V. KANDEL, M.D.; G. V. LEROY, M.D.

Arch Intern Med. 1937;60(5):846-866.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The value of inorganic arsenical preparations in the treatment of chronic myeloid leukemia was neglected in the American medical literature from the time that roentgen therapy was suggested by Nicholas Senn¹ until the report of Forkner and Scott² in 1931. The 1931 report described a favorable reaction in nine of ten patients receiving solution of potassium arsenite in subtoxic amounts. Later Forkner³ described its successful use in eighteen patients, none of whom had received the drug for longer than one year. In 1936 Stephens and Lawrence⁴ reported on seven patients treated successfully for about four years or less. The early authors encountered no complications more serious than transient conjunctivitis, coryza, nausea and diarrhea. One patient had herpes zoster while taking arsenic, but the authors considered that this was as likely to be a feature of the leukemia as a result of the treatment. One of the . . . [Full Text PDF of this Article]

Author Affiliations
CHICAGO

From the Department of Hematology, the University of Chicago.

Footnotes
Douglas Smith Foundation Research Fellow.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?